We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Adaptation of Aspergillus Presents Doctors with Dilemma

By LabMedica International staff writers
Posted on 14 Oct 2016
Aspergillus fumigatus causes a range of diseases in human beings, some of which are characterized by fungal persistence and the fungus can persist by adapting to the human lung environment through physiological and genomic changes.

The physiological changes are based on the large biochemical versatility of the fungus, and the genomic changes are based on the capacity of the fungus to generate genetic diversity by spontaneous mutations or recombination and subsequent selection of the genotypes that are most adapted to the new environment.

Scientists at the Radboud University Medical Center (Nijmegen, Netherlands) and their colleagues suggest that any change can stimulate the fungus to adapt. More...
This applies equally to starting a new treatment, substituting one antifungal medication for another or entirely stopping treatment. Knowing that all environmental changes can stimulate adaptation in the fungus poses a problem for doctors. Treating the fungus with medication could lead to drug resistance, but not treating the fungus or discontinuing the initial treatment makes it easier for the fungus to settle in the lungs. Either one of these options may make it difficult to eradicate the fungus from the patient.

The team explored the adaptation strategies of A. fumigatus in relation to azole resistance selection and the clinical implications thereof for management of diseases caused by Aspergillus spp. The emphasis of the study was what primarily affects lung patients who are long-term carriers of the Aspergillus fungus, such as patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Stress factors, such as triazole exposure, cause mutations that render resistance. The process of reproduction that is sexual, parasexual, or asexual, is probably crucial for the adaptive potential of Aspergillus spp. As any change in the environment can provoke adaptation, switching between triazoles in patients with chronic pulmonary aspergillosis might result in a high-level pan-triazole-resistant phenotype through the accumulation of resistance mutations. These results call for a modification of the current treatment guidelines.

A similar adaptation is expected to occur in response to other stress factors, such as endogenous antimicrobial peptides; over time the fungus will become increasingly adapted to the lung environment, thereby limiting the probability of eradication. The group’s hypothesis challenges current management strategies, and future studies should investigate the genomic dynamics during infection to understand the key factors facilitating adaptation of Aspergillus spp. The study was published on September 13, 2016, in the journal The Lancet Infectious Diseases.

Related Links:
Radboud University Medical Center


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.